- Lifecore Biomedical has signed an agreement with a leading global pharmaceutical company to transfer commercial manufacturing of an injectable drug to its facilities.
- The company also announced a new partnership with an early-stage biotechnology firm for pre-clinical formulation development.
Lifecore Biomedical, Inc. has announced an agreement with a leading global pharmaceutical company to take over commercial manufacturing for a key injectable pharmaceutical product. The transfer will move production from the current manufacturer to Lifecore’s facilities, with the company becoming the commercial supplier of choice once regulatory requirements are met.
This marks the second agreement between Lifecore and the same multinational company in recent months, underscoring its growing reputation for technical excellence and reliability in sterile injectables.
“This commercial site transfer is a significant accomplishment in our ongoing growth strategy as we work to expand our CDMO business and build long-term partnerships with leading global pharmaceutical companies.”
Paul Josephs, Chief Executive Officer of Lifecore
The agreement supports Lifecore’s broader CDMO growth strategy, which focuses on increasing capacity utilisation, expanding into new modalities, and strengthening its commercial customer base.
In a separate development, the company signed an additional agreement with an early-stage biotechnology firm to provide pre-clinical formulation development services, further expanding its early-stage project pipeline.
Josephs added that Lifecore’s continued momentum reflects its role as a trusted U.S.-based CDMO partner supporting domestic manufacturing for sterile injectables.
